PURPOSE: Postmastectomy radiotherapy (PMRT) improves locoregional control (LRC) in patients with high-risk features after mastectomy. Young age continues to evolve as a potentially important risk factor. The objective of this study was to assess the benefits of PMRT in patients <35 years old treated with doxorubicin-based neoadjuvant chemotherapy for Stage II-III breast cancer. PATIENTS AND METHODS: We retrospectively analyzed 107 consecutive breast cancer patients <35 years old with Stage IIA-IIIC disease treated at our institution with doxorubicin-based neoadjuvant chemotherapy and mastectomy, with or without PMRT. The treatment groups were compared in terms of LRC and overall survival. RESULTS: Despite more advanced disease stages, the patients who received PMRT (n = 80) had greater rates of LRC (5-year rate, 88% vs. 63%, p = 0.001) and better overall survival (5-year rate, 67% vs. 48%, p = 0.03) than patients who did not receive PMRT (n = 27). CONCLUSION: Among breast cancer patients <35 years old at diagnosis, the use of PMRT after doxorubicin-based neoadjuvant chemotherapy and mastectomy led to a statistically greater rate of LRC and overall survival compared with patients without PMRT. The benefit seen for PMRT in young patients provides valuable data to better tailor adjuvant, age-specific treatment decisions after mastectomy.
PURPOSE: Postmastectomy radiotherapy (PMRT) improves locoregional control (LRC) in patients with high-risk features after mastectomy. Young age continues to evolve as a potentially important risk factor. The objective of this study was to assess the benefits of PMRT in patients <35 years old treated with doxorubicin-based neoadjuvant chemotherapy for Stage II-III breast cancer. PATIENTS AND METHODS: We retrospectively analyzed 107 consecutive breast cancerpatients <35 years old with Stage IIA-IIIC disease treated at our institution with doxorubicin-based neoadjuvant chemotherapy and mastectomy, with or without PMRT. The treatment groups were compared in terms of LRC and overall survival. RESULTS: Despite more advanced disease stages, the patients who received PMRT (n = 80) had greater rates of LRC (5-year rate, 88% vs. 63%, p = 0.001) and better overall survival (5-year rate, 67% vs. 48%, p = 0.03) than patients who did not receive PMRT (n = 27). CONCLUSION: Among breast cancerpatients <35 years old at diagnosis, the use of PMRT after doxorubicin-based neoadjuvant chemotherapy and mastectomy led to a statistically greater rate of LRC and overall survival compared with patients without PMRT. The benefit seen for PMRT in young patients provides valuable data to better tailor adjuvant, age-specific treatment decisions after mastectomy.
Authors: M Clarke; R Collins; S Darby; C Davies; P Elphinstone; V Evans; J Godwin; R Gray; C Hicks; S James; E MacKinnon; P McGale; T McHugh; R Peto; C Taylor; Y Wang Journal: Lancet Date: 2005-12-17 Impact factor: 79.321
Authors: Joseph Ragaz; Ivo A Olivotto; John J Spinelli; Norman Phillips; Stewart M Jackson; Kenneth S Wilson; Margaret A Knowling; Christopher M L Coppin; Lorna Weir; Karen Gelmon; Nhu Le; Ralph Durand; Andrew J Coldman; Mohamed Manji Journal: J Natl Cancer Inst Date: 2005-01-19 Impact factor: 13.506
Authors: S Aebi; S Gelber; M Castiglione-Gertsch; R D Gelber; J Collins; B Thürlimann; C M Rudenstam; J Lindtner; D Crivellari; H Cortes-Funes; E Simoncini; I D Werner; A S Coates; A Goldhirsch Journal: Lancet Date: 2000-05-27 Impact factor: 79.321
Authors: Eugene H Huang; Susan L Tucker; Eric A Strom; Marsha D McNeese; Henry M Kuerer; Aman U Buzdar; Vicente Valero; George H Perkins; Naomi R Schechter; Kelly K Hunt; Aysegul A Sahin; Gabriel N Hortobagyi; Thomas A Buchholz Journal: J Clin Oncol Date: 2004-12-01 Impact factor: 44.544
Authors: A J Nixon; D Neuberg; D F Hayes; R Gelman; J L Connolly; S Schnitt; A Abner; A Recht; F Vicini; J R Harris Journal: J Clin Oncol Date: 1994-05 Impact factor: 44.544
Authors: A de la Rochefordiere; B Asselain; F Campana; S M Scholl; J Fenton; J R Vilcoq; J C Durand; P Pouillart; H Magdelenat; A Fourquet Journal: Lancet Date: 1993-04-24 Impact factor: 79.321
Authors: Amit K Garg; Eric A Strom; Marsha D McNeese; Aman U Buzdar; Gabriel N Hortobagyi; Henry M Kuerer; George H Perkins; S Eva Singletary; Kelly K Hunt; Asyegul Sahin; Naomi Schechter; Vicente Valero; Susan L Tucker; Thomas A Buchholz Journal: Int J Radiat Oncol Biol Phys Date: 2004-05-01 Impact factor: 7.038
Authors: Frederik Wenz; Elena Sperk; Wilfried Budach; Jürgen Dunst; Petra Feyer; Rainer Fietkau; Wulf Haase; Wolfgang Harms; Marc D Piroth; Marie-Luise Sautter-Bihl; Felix Sedlmayer; Rainer Souchon; Christoph Fussl; Rolf Sauer Journal: Strahlenther Onkol Date: 2014-08 Impact factor: 3.621
Authors: Kennya Medeiros L de B Lima; Allan A Lima Pereira; Thiago B de Freitas; Saulo Brito Silva; Heloisa de Andrade Carvalho; Max S Mano; Gustavo Nader Marta Journal: Rep Pract Oncol Radiother Date: 2018-11-28
Authors: Gustavo Nader Marta; Reem AlBeesh; Allan A Lima Pereira; Leandro Jonata Oliveira; Max S Mano; Tarek Hijal Journal: Breast Date: 2020-08-29 Impact factor: 4.380